Evaluation of adjuvants for protein vaccines against tuberculosis in guinea pigs

Vaccine

Volumn 21, Issue 9-10, 2003, Pages 977-982

  Hogarth, Philip J ^a   Jahans, Keith J ^a   Hecker, Rolf ^b   Hewinson, R Glyn ^a   Chambers, Mark A ^a  

^a VETERINARY LABORATORIES AGENCY   (United Kingdom)

^b QIAGEN GMBH   (Germany)

Author keywords

Immunogenic; Mycobacteria; T cell response

Indexed keywords

ADJUVANT; CPG OLIGODEOXYNUCLEOTIDE; CULTURE FILTRATE PROTEIN; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; FREUND ADJUVANT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; MONOPHOSPHORYL LIPID A TREHALOSE DICORYNOMYCOLATE; TOMATINE; UNCLASSIFIED DRUG; VACCINE;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; CELLULAR IMMUNITY; CONFERENCE PAPER; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; DRUG SCREENING; EMULSION; FEMALE; GUINEA PIG; HUMORAL IMMUNITY; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MYCOBACTERIUM BOVIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TH1 CELL; TUBERCULOSIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; DRUG EVALUATION, PRECLINICAL; FEMALE; GUINEA PIGS; HYPERSENSITIVITY, DELAYED; IMMUNOGLOBULIN G; LYMPHOCYTE ACTIVATION; OLIGODEOXYRIBONUCLEOTIDES; T-LYMPHOCYTES; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, SUBUNIT;

EID: 0037435891     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00548-0     Document Type: Conference Paper

References (36)

1. Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organisation. Tubercle. 72:1991;1-6.
2. Krebs J, Anderson R, Clutton-Brock T, Morrison I, Young D, Donelly C. Bovine tuberculosis in cattle and badgers. Ministry of Agriculture Fisheries and Food; 1997.
3. Bloom BR, Fine PEM. The BCG experience: implications for future vaccines against tuberculosis. In: Bloom BR, editors. Tuberculosis: pathogenesis, protection and control. Washington (DC): ASM Press; 1994. p. 531-57.
4. Vordermeier H.M., Chambers M.C., Cockle P.J., Whelan A.O., Hewinson R.G., Correlation of ESAT-6 specific IFN-γ production with pathology in cattle following BCG vaccination against experimental bovine tuberculosis Infect. Imm. 70:2002;3026-3032.
5. Mazurek G.H., LoBue P.A., Daley C.L.et al. Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterial tuberculosis infection. JAMA. 286:2001;1740-1747.
6. Vordermeier H.M., Whelan A.O., Cockle P.J., Farrant L., Palmer N., Hewinson R.G. Use of synthetic peptides derived from the antigens ESAT-6 and CFP-10 for differential diagnosis of bovine tuberculosis in cattle. Clin. Diag. Lab. Immunol. 8:2001;571-578.
7. Orme I.M., McMurray D.N., Belisle J.T. Tuberculosis vaccine development: recent progress. Trends Microbiol. 9:2001;115-118.
8. Brooks J.V., Frank A.A., Keen M.A., Bellisle J.T., Orme I.M. Boosting vaccine for tuberculosis. Infect. Immun. 69:2001;2714-2717.
9. Feng C.G., Palendira U., Demangel C., Spratt J.M., Malin A.S., Britton W.J. Priming by DNA immunisation augments protective efficacy of Mycobacterium bovis bacille Calmette-Guerin against tuberculosis. Infect. Immun. 69:2001;4174-4176.
10. Audibert F.M., Lise L.D. Adjuvants: current status, clinical perspectives and future prospects. Immunol. Today. 14:1993;281-284.
11. Kauffman S.H.E., Andersen P. Immunity to mycobacteria with emhasis on tuberculosis: implications for rational design of an effective tuberculosis vaccine. Chem. Immunol. 70:1998;21-59.
12. Andersen P. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect. Immun. 62:1994;2536-2544.
13. Lindblad E.B., Elhay M.J., Silva R., Appleberg R., Andersen P. Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect. Immun. 65:1997;623-629.
14. Baldwin S.L., D'Souza C., Roberts A.D.et al. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infect. Immun. 66:1998;2951-2959.
15. Brandt L., Elhay M., Rosenkrands I., Lindblad E.B., Andersen P. ESAT-6 subunity vaccination against Mycobacterium tuberculosis. Infect. Immun. 68:2000;791-795.
16. Horwitz M.A., Lee B.E., Dillon B.J., Harth G. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA. 92:1995;1530-1534.
17. McMurray DN. Guinea pig model of tuberculosis. In: Bloom BR, editors. Tuberculosis: pathogenesis, protection and control. Washington (DC): ASM Press; 1994. p. 135-47.
18. Chambers M.A., Williams A., Gavier-Widen D.et al. A guinea pig model of low-dose Mycobacterium bovis aerogenic infection. Vet. Micro. 80:2001;213-226.
19. Hubbard R.D., Flory C.M., Collins F.M. Immunisation of mice with mycobacterial culture filtrate proteins. Clin. Exp. Immunol. 87:1992;94-98.
20. Pal P.G., Horwitz M.A. Immunisation with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis. Infect. Immun. 60:1992;4781-4792.
21. Bosio C.M., Orme I.M. Effective, nonsensitising vaccination with culture filtrate proteins against virulent Mycobacterium bovis infections in mice. Infect. Immun. 66:1998;5048-5051.
22. Wedlock D.N., Vesosky B., Skinner M.A., DeLisle G.W., Orme I.M. Vaccination of cattle with Mycobacterium bovis culture filtrate proteins and interleukin-2 for protection against bovine tuberculosis. Infect. Immun. 68:2000;5809-5815.
23. Rajananthanan P., Attard G.S., Sheikh N.A., Morrow W.J.M. Evaluation of novel aggregate structures as adjuvants: composition, toxicity studies and humoral responses. Vaccine. 17:1999;715-730.
24. World Health Organisation. Biological Substances: International Standards And Reference Regents. Geneva: World Health Organisation; 1990.
25. Gupta R.K., Relyveld E.H., Lindblad E.B., Bizzini B., Ben-Efraim S., Gupta C.H. Adjuvants-a balance between toxicity and adjuvanticity. Vaccine. 11:1993;293-306.
26. Snapper CM, Finkelman FD, Immunoglobulin class switching. In: Paul WE, editors. Fundamental immunology. New York: Lippincott-Raven; 1998. p. 831-61.
27. Snapper C.M., Paul W.E. Interferon-γ and B cell stimulatory factor-1 recipricolly regulate Ig isotype production. Science. 236:1987;944-947.
28. Kawano Y., Noma T., Yata J. Regulation of human IgG subclass production by cytokines. J. Immunol. 153:1994;4948-4958.
29. Estes D.M. Differentiation of B cells in the bovine. Role of cytokines in immunoglobulin isotype expression. Vet. Immunol. Immunopath. 54:1996;61-67.
30. Sheikh N.A., Rajananthanan P., Attard A.S., Morrow W.J.W. Generation of antigen specific CD8+ cytotoxic T cells following immunisation with soluble protein formulated with novel glycoside adjuvants. Vaccine. 17:1999;2974-2982.
31. Heal K.G., Sheikh N.A., Hollingdale M.R., Morrow W.J., Taylor-Robinson A.W. Potentiation by a novel alkaloid glycoside adjuvant of a protective cytotoxic T cell immune response specific for a preerythrocytic malaria antigen. Vaccine. 19:2001;4153-4161.
32. Roman M., Martin-Orozco E., Goodman J.S.et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nature Med. 3:1997;849-854.
33. Pontarollo R.A., Rankin R., Babiuk L.A.et al. Monocytes are required for optimum in vitro stimulation of bovine peripheral blood mononuclear cells by non-methylated CpG motifs. Vet. Immunol. Immunopathol. 84:2002;43-59.
34. Hartmann G., Krieg A.M. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J. Immunol. 164:2000;944-953.
35. Hartmann G.R.D.W., Ballas Z.K.et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J. Immunol. 164:2000;1617-1624.
36. Rankin R., Pontarollo R., Ioannou X.et al. CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev. 11:2001;333-340.